AI assistant
SCI Interim / Quarterly Report 2023
52383_rns_2024-01-31_e71bc451-f6c4-4719-85fa-86a0e9a1cd61.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
公司概況Profile
- 產能Capacity:
- 2021:0,2022:5~35%,2023:35~65%,2024 Feb.: completed
- 員工數Employee:255
- 設立日期:中華民國七十六年九月十八日
- Date of establishment: Sep. 18, 1987
- 資本額Capital:新台幣1,195佰萬元(NTD 1,195mn)
- 營業項目Business:
- 原料藥API(59.65%)
- 中間體Intermediate(39.17%)
- 其他 Other chemicals(1.18%)
產品組合-Products
| Sales Product | % | 2023Y ( K NT\$) |
|---|---|---|
| PGA | 26.0% | 313,184 |
| VA series | 25.2% | 303,219 |
| Pent-2 / PEB.Na | 24.4% | 293,838 |
| BZA | 8.3% | 100,190 |
| Dulo.Hcl | 5.4% | 65,168 |
| PF.Hcl | 4.0% | 47,786 |
Unit: K NTD
| 2023.Q1~Q3 | |
|---|---|
| 營收Sales | 912,743 |
| 營業成本COGS | (629,815) |
| 毛利Gross Profit | 282,928 |
| 毛利率 GP Ratio | 31.0% |
| 營業費用Operating Expenses | (131,539) |
| 營業利益Operating Income | 151,389 |
| 營業外損益Non-Operating In/Ex | 223,094 |
| 稅前淨利 Net Profit before Tax | 374,483 |
| 所得稅Income Tax | (76,151) |
| 本期淨利Net Profit after Tax | 298,332 |
Pyrogallolaldehyde ( PGA)
Benserazide
治療帕金森氏症之中間體
Intermediate for Parkinson's Disease
VA Series:
Valproic Acid, Divalproex Sodium, Sodium Valproate
適應症 Application: 癲癇(seizure)、躁鬱症(bipolar disorder)、 偏頭痛(migraine headaches)
Pent-2 / Pentobarbital Sodium
鎮定安眠用中間體及原料藥 Intermediate and API for calmative
Brinzolamide
青光眼原料藥 API for Glaucoma medication
Duloxetine HCl
適應症 Application: 重鬱症(major depressive disorder)、廣泛性焦慮症 (generalized anxiety disorder) 、糖尿病週邊神經痛 (diabetic neuropathy) 、纖維肌痛(Fibromyalgia)、 慢性腰痛(日本地區) lower back pain (only in Japan)
Hydroxychloroquine sulfate
適應症 Application: 類風濕性關節炎(rheumatoid arthritis) 、瘧疾 (malaria)、 慢性多形性日光疹、慢性圓板狀紅斑症 (discoid and systemic lupus erythematosus)
新品項(New Products)
- Buprenorphine
- 止痛劑(Painkiller) 、治療鴉片類物質成癮 (Opioid use addiction)
- LMTM
阿茲海默症藥物(Alzheimer's disease medicine)
- 大麻二酚 Cannobidiol 癲癇藥物 (Epidiolex)
- 嗜睡症藥物 (Narcolepsy)
- 腺嘌呤 (Adenine)
- Pimobendan
寵物心臟病藥物(Heart disease medicine for pets)
觀音廠&法蘭摩沙(Guanyin Plant and Framosa)
| No.1 | API | DMF (USA) |
CEP (EDQM) |
KDMF (Korea) |
MF (Japan) |
DMF (Canada) |
CGMP certified (TFDA) |
GMP certificate (Brazil) |
China DMF | Brazil DMF |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Adenine | 2022 | ||||||||
| 2 | Articaine Hydrochloride |
2014 | 2014 | 2023 | 2013 | 2021 | ||||
| 3 | Allopurinol | 2011 | 2003 | 2004 | ||||||
| 4 | Atomoxetine Hydrochloride | 2018 | 2018 | 2016 | ||||||
| 5 | Bisoprolol Fumarate | 2006 | ||||||||
| 6 | Brinzolamide | 2015 | 2023 | 2017 | 2022 (GDP) | 2023 | 2023 | |||
| 7 | Clindamycin Palmitate HCl | 2011 | ||||||||
| 8 | Divalproex Sodium | 2005 | 2010 | 2022 (GDP) | 2023 | 2010 | ||||
| 9 | Duloxetine Hydrochloride | 2011 | 2014 | 2017 | 2016 | 2022 (GDP) | 2023 | 2013 | ||
| 10 | Hydroxychloroquine Sulfate | 2014 | 2019 | 2014 | 2014 | 2023 | 2020 | |||
| 11 | Loxoprofen Sodium Hydrate | 2011 | 2012 | 2023 | 2023 | |||||
| 12 | Methylphenidate HCl | 2014 | 2022 (GDP) | 2023 | ||||||
| 13 | Pentobarbital Sodium | 2011 | 2022 (GDP) | |||||||
| 14 | Probucol | 2004 | 2017 | 2015 | 2022 (GDP) | 2023 | ||||
| 15 | Propafenone Hydrochloride | 2010 | 2012 | 2012 | 2012 | 2022 (GDP) | 2023 | 2018 | ||
| 16 | Sodium Valproate | 2019 | 2006 | 2017 | 2022 (GDP) | 2023 | 2014 | |||
| 17 | Thiopental | 2020 | ||||||||
| 18 | Valproic Acid | 2003 | 2004 | 2008 | 2008 | 2022 | 2023 | 2023 | ||
| 19 | Cannabidiol (CBD) | 2020 | 2020 | |||||||
| No.2 | API intermediate | DMF (USA) |
CEP (EDQM) |
MF (Japan) |
DMF (Canada) |
CGMP certified (TFDA) |
||||
| 1 | Menthadienol (PMDOL) | 2019 | ||||||||
| 2 | Olivetol | 2019 | ||||||||
| 3 | Ethyl Olivetolate | 2019 |
